Sovargen doses first patient in paxalisib epilepsy trial, triggers $2M payment to Kazia
The Phase 1b/2a study targets rare seizure disorders linked to mTOR pathway overactivation, expanding paxalisib beyond its oncology roots.
SEC filing
Latest
2 stories
Tuesday, September 22
Monday, August 31
Kazia files final prospectus, discloses new details on TNBC data and share count after $40M offering
A prospectus supplement filed alongside the priced offering adds interim TNBC trial results and updated share counts, while confirming warrant terms tied to two future data readouts.
SEC filing (4)